We hypothesize that 1) SDF-1 boosts MIC growth and protects MICs from chemotherapy-induced injury; and further drives the lineage process of multiple myeloma [11]; 2) myeloma-BMSC interaction induced secretion of TGFβ, which suppress the immune response during myeloma development. Here, CXCL12 is linked to plasma cell myeloma.